Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 48 |
| Active Pipeline (Recruiting Now) | 26 (20) |
| Completed vs Stopped Early | 10 / 6 (12.5%) |
| Median Closed Actual Enrollment | 51 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sunnybrook Health Sciences Centre | Toronto, Ontario | 31 |
| The Ottawa Hospital | Ottawa, Ontario | 7 |
| London Health Sciences Centre | London, Ontario | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03559114 | PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST) | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Sunnybrook Health Sciences Centre Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.